



## Lead induced Oxidative Stress Mediated Myocardial Injury: A Review

Debasish Bandyopadhyay<sup>1\*</sup>#, Debosree Ghosh<sup>1</sup>, Aindrila Chattopadhyay<sup>2</sup>

<sup>1</sup> Department of Physiology, University of Calcutta, University College of Science and Technology, 92, APC Road, Kolkata, India.

<sup>2</sup> Department of Physiology, Vidyasagar College, 39, Sankar Ghosh Lane, Kolkata, India.

#Principal Investigator, Centre with Potential for Excellence in a Particular Area (CPEPA), University of Calcutta, University College of Science and Technology, 92 APC Road, Kolkata, India.

\*Corresponding author's E-mail: [debasish63@gmail.com](mailto:debasish63@gmail.com)

Accepted on: 26-09-2014; Finalized on: 30-11-2014.

### ABSTRACT

Lead is a naturally occurring toxic element. It has several industrial uses and is highly toxic for living organisms if it enters and accumulates in body. Long term exposure to this heavy metal either environmentally or occupationally may cause various types of ailments among which myocardial injury and hepato-toxicity are worth mentioning. Lead induced myocardial injury occurs primarily through lead mediated oxidative damage of myocardial tissue. Lead stimulates generation of reactive oxygen species (ROS) which causes biochemical, cytological and physiological detrimental alterations of the cardiac tissue. Administration or supplementation of antioxidant rich aqueous curry leaves (a popular spice herb, *Murraya koenigii*) extract and melatonin, a natural indole, separately have the potentiality to provide protection against lead induced myocardial damage. Their combination can provide a stronger protection against myocardial damage brought about following exposure to lead and the protection is almost complete. Thus, we can think of designing a potent drug formulation with very low or no toxicity against lead induced oxidative stress mediated myocardial injury using aqueous curry leaves extract and melatonin in combination which may have future therapeutic relevance.

**Keywords:** Lead, Myocardial injury, toxic element.

### INTRODUCTION

In spite of marked therapeutic advancement, cardiac ailments are still remaining to be one of the significant causes of death of millions around the globe<sup>1</sup>. Mortality due to cardiac failure is more in developed countries and the rate is increasing in the developing countries like India<sup>2</sup>. The causes underneath such cardiovascular pathogenesis have been recognised to be many. Involvement of insulin resistance and diabetic cardiomyopathy<sup>3</sup>, altered lipid profile<sup>5</sup>, obesity, altered life style, dietary habits<sup>6</sup> have been found to be the major contributors. Molecular genomic study reveals genetic predisposition for cardiac arrest and ailments<sup>7</sup>. Environmental toxin induced oxidative stress mediated cardiac disorders and ischemic changes has been extensively evaluated and established in various models<sup>8</sup>.<sup>9</sup> Our studies also revealed the involvement of heavy metal induced oxidative stress mediated damage in cardiac tissues of male Wistar rats<sup>10-13</sup>.

Lead is an old environment pollutant and the history of lead poisoning is almost 2500 years old<sup>14</sup>. Lead exposure occurs either environmentally or occupationally or by both routes<sup>15</sup>. Children are more susceptible to lead toxicity<sup>16</sup>. Chronic lead poisoning has been found to be associated with hypertension, altered lipid profile, arteriosclerosis and cardiac ailments<sup>17</sup>. Lead once absorbed and if not excreted enters and gets accumulated mainly in three types of tissues i.e., blood, soft tissues (liver, kidneys, brain, heart) and mineralizing tissues (bones and teeth)<sup>18</sup>. We have found through atomic absorption spectrophotometric studies that lead

accumulated in the heart tissues and, lead induced oxidative stress plays a significant role in ischemic changes in heart<sup>10,11</sup> and other organs as well<sup>19</sup>. We have also evaluated *in vitro* the involvement of oxidative stress in lead induced damages in heart<sup>20</sup>. We observed marked alterations in the activities of antioxidant enzymes in cardiac tissues following lead exposure in both *in vitro* and *in vivo* models<sup>10,11,20</sup>. The level of lead in blood has been found to be associated with increased blood pressure<sup>21</sup>. Most of the blood lead is known to be accumulated inside red blood cells<sup>22</sup>. The level of lead in bones has also been evaluated and found to be related with hypertension in individuals<sup>23</sup>. We found altered lipid profile and changes in blood parameters with lead acetate treatment of rats for seven consecutive days<sup>24</sup>. Hypertension and changes in lipid profile are considered as precursors of myocardial injuries<sup>21,22,23</sup>.

### Myocardial injury

The myocardium is the muscular tissue of the heart. Myocardial injury can be of various types and may lead to various cardio-myopathic conditions i.e., arrhythmia, shock, necrosis, ischemia, infarction and failure<sup>25</sup>. The myocardium is supplied blood by the two major coronary arteries and their branches. Blockage of any of these blood vessels is accounted as one of the prime cause of myocardial infarction.

Occlusion or blockage of any of these coronary vessels may result as a cause of clotting of blood or due to deposition of cholesterol inside blood vessel which ultimately narrows the vessel, lessens its elasticity and leads to blood clotting inside vessel. Inadequate or




stoppage of blood supply to the cardio-myocytes causes ischemia which can be in a small area and is termed as “focal ischemia” or if a large area of the myocardium is deprived of blood supply then it leads to “global ischemia”. Extended and undiagnosed ischemia leads to myocardial infarction. Damage of the cyto-architecture of the cardio-myocytes or the endothelial cells of the coronary vessels by any means may lead to functional inadequacy of the tissues (Fig.1) <sup>26</sup>.

The most common type of heart disease in the developed countries is the coronary artery disease (CAD) <sup>27</sup> and men are more susceptible than women <sup>27</sup>. Studies reveal an increasing report of CAD in the developing countries these days <sup>28</sup>.

### Lead toxicity and myocardial injury: involvement of oxidative stress

Studies reveal incidence of myocardial injury due to occupational or environmental exposure to toxins like combustion particulates <sup>29</sup> and heavy metals <sup>30</sup>. Air pollution has been found to be associated with increased morbidity due to cardiovascular diseases and early mortality as well <sup>29</sup>. Histo-morphological studies revealed that particulate matter caused marked injury and inflammatory changes in myocardial tissue of experimental rats <sup>29</sup>. Heavy metals like lead, cadmium and arsenic have also been found to be associated with myocardial injuries <sup>10-13, 31</sup>. We have also observed significant focal ischemia in heart tissues of male Wistar rats when exposed to lead acetate for seven consecutive days (Fig.1) <sup>10, 11</sup>.



**Figure 1:** Section of rat heart stained with ‘Eosin-Hematoxylin stain’ (400 X,) showing lead induced myocardial ischemia due to exposure of the animals to lead acetate for seven consecutive days. Image captured using Magnus MLX DX 4B522434.


The mechanism of lead induced cardio-toxicity is considered multifaceted and multi-factorial <sup>32</sup>. After extensive research worldwide, it is inferred that lead mediated oxidative stress is a major contributor of lead toxicity <sup>32</sup>. Our studies showed that lead (administered to experimental rats in the form of lead acetate) increases the level of peroxidation of the membrane lipids of the cardio-myocytes and also increases the level of carbonylation of the proteins <sup>10, 11</sup>. This is brought about by lead induced generation of reactive oxygen species (ROS) which is evident from increase in the activity of the pro-oxidant enzymes i.e., xanthine oxidase and xanthine

dehydrogenase in cardiac tissues <sup>10, 11</sup> of rats treated with lead acetate. Increased activity of the serum glutamate oxaloacetate transaminase (SGOT) is associated with lead toxicity which is a clinical marker of cardiac damage <sup>10, 11</sup>. We have also found that treatment of rats with lead acetate for seven consecutive days causes a decrease in size of the heart <sup>10, 11</sup>. Thus, lead has a tendency of inducing myocardial hypotrophy.

The ROS are recognised as potent inducers of DNA damage which leads to atherosclerotic changes in vessels and other deteriorative changes in cardio-myocytes. There is report of ‘macro’ DNA damage within atherosclerotic plaques <sup>33</sup>. The ROS induced mitochondrial DNA damage has been found to bear relationship with the extent of occurrence of atherosclerosis in human specimens <sup>34</sup>. The ROS has also been reported to cause mitochondrial DNA damage in aortas from ApoE(-/-) mice. Disruption of the antioxidant enzyme viz., manganese superoxide dismutase (Mn-SOD), a mitochondrial enzyme, indicates increased mitochondrial DNA damage and accelerated atherogenesis at arterial branch points <sup>34</sup>. Oxidative DNA damage increases with exposure to toxins <sup>35</sup>. We have found in our experimental models, marked damage of DNA isolated from heart of male Wistar rats, exposed to lead acetate for seven consecutive days. The ROS causes myocyte hypertrophy, apoptosis, and interstitial fibrosis by activating matrix metallo-proteinases. This event in the cardio-myocytes contributes significantly to development and progression of maladaptive cardiac remodeling and failure <sup>36</sup>. Lead exposure has also been reported to be related to clinical cardiovascular end points such as coronary heart disease, stroke, and peripheral arterial disease <sup>37-39</sup> and with other cardiovascular function abnormalities like left ventricular hypertrophy and changes in cardiac rhythm <sup>40, 41</sup>. A change in the lipid profile is considered a significant event in the pathogenesis and progression of atherosclerosis and cardiovascular diseases <sup>42, 43</sup>. We have also observed changes in total cholesterol, triglyceride, HDL cholesterol, LDL cholesterol, total cholesterol: HDL cholesterol, LDL cholesterol: HDL cholesterol in experimental rats when treated with lead acetate for seven consecutive days <sup>24</sup>. However, the mechanism underlying reduction of heart size in our experiments currently remains poorly understood and needs further exploration.

Lead has been known to cause inflammation by activating nuclear factor Kappa B (NFkB) via oxidative stress. The NFkB is a general transcription factor for various cytokines, chemokines and adhesion molecules. Thus, by activation of NFkB, oxidative stress can cause inflammation. Lead induced generation of ROS may trigger a cycle of oxidative stress and inflammation in the target tissues <sup>22</sup>. Studies showed increased level of plasma norepinephrine (NE) in lead exposed workers and thus, revealed stimulatory role of lead on the sympathetic nervous system and its contribution to the cardiovascular effects <sup>44</sup>. Lead has been reported to have effects on renin-angiotensin and kininergic systems. A marked

increase in the activity of angiotensin converting enzyme (ACE) in plasma and cardiac tissue has been reported following lead exposure at early age in experimental rats<sup>45</sup>. Thus, a correlation between activation of renin angiotensin system at some point in the course of lead-induced hypertension (HTN) is well interpreted. An interrelationship of nitric oxide (NO<sup>\*</sup>) and ROS is known to be a major contributor in lead induced hypertension<sup>46</sup>. Reduction in NO<sup>\*</sup> bioavailability by lead exposure is mediated by oxidative stress<sup>47</sup>. Effect of lead on prostaglandins, viz., endothelin (ET) and atrial natriuretic peptide (ANP) has also been studied<sup>48, 49</sup>. Lead exposure has been found to cause a significant increase of the metabolite of vaso-constrictive prostaglandin, thromboxane (TXB<sub>2</sub>), in urine of lead exposed workers<sup>48</sup>. *In vitro* studies showed that lead induces release of arachidonic acid by vascular smooth cells through activation of phospholipase A<sub>2</sub><sup>49</sup>. Lead has also been reported to cause an elevation in the content of endothelin in rat vascular tissue<sup>50</sup>. Lead-dependent effects on arachidonic acid accumulation and the proliferation of vascular smooth muscle has also been studied<sup>51</sup>. Atrial natriuretic peptide (ANP) is a vasodilator secreted by cardio-myocytes and is a natriuretic agent. Studies revealed that lead induces dysregulation of ANP which has been found to be a contributing factor of cardiovascular toxicity<sup>52</sup>. Lead has been found to cause vasoconstriction in isolated rabbit mesenteric artery<sup>53</sup>. Lead-calcium interaction in vascular tissue has also been observed<sup>54</sup>. Lead has been reported to be a potential competitor of Ca<sup>2+</sup> and competes for the transport by channels and pumps across the cell membrane and between cytoplasm, endoplasmic reticulum and mitochondria<sup>54, 55</sup>. Besides, lead has been recognised to be acting as a substitute for calcium in Ca<sup>2+</sup>-dependent signalling pathways and it interacts with calmodulin, PKC and calcium-dependent potassium channels<sup>55</sup>. These interactions of lead with cellular Ca<sup>2+</sup> in the vascular cells may be considered to be responsible for alterations of vascular resistance and cardiovascular disorders (Fig.2).



**Figure 2:** Scheme showing how lead induced oxidative stress mediates myocardial injury.

NFkB = nuclear factor Kappa B; HTN = hypertension; TXB<sub>2</sub> = thromboxane; ANP = Atrial natriuretic protein; Ca<sup>2+</sup> = calcium ion;

## Concluding remarks

Unavoidable exposure to lead environmentally or occupationally can cause generation of ROS *in vivo* and damages the myocardium leading to myocardial ischemic changes and infarction. Protection against myocardial injury has been investigated for years and researchers have come up with therapeutic solutions to the problem among which reperfusion therapy has been widely accepted and practised widely in spite of reported side effects i.e., reperfusion injury. Sudden perfusion of ischemic cardiac tissue during reperfusion therapy stimulates generation of myriads of ROS which causes further damage of the tissue<sup>56</sup>.

We investigated protective measures against lead induced myocardial injury and found that aqueous curry leaves extract and melatonin, a small molecular weight indole with proven antioxidant efficacy, possess excellent protective action against lead induced oxidative stress mediated myocardial injury when tested separately<sup>10, 11</sup>. We have further examined that whether a combination of melatonin and aqueous curry leaves extract act together in a better manner to ameliorate lead induced myocardial injury. We have found that the combination complement the antioxidant potential of each other and act synergistically to protect against lead induced oxidative stress mediated hepatic and cardiac damage and antioxidant mechanisms are associated with such protection<sup>57</sup>.

Both melatonin and aqueous curry leaves extract have no reported cyto-toxicity and have minimal or no side effects. The combination appears to be a better and safer option to prevent as well as protect against lead induced myocardial injury in humans expose to lead occupationally or environmentally although further studies in human situations are needed.

Antioxidant supplementation has already been recently adapted by cardiologists to optimise the conditions of various myocardial injuries. The future use of aqueous extract of curry leaves and melatonin individually or in combination may be an important step toward development of an important therapeutic strategy to fight against lead induced myocardial injury. Aqueous curry leaves extract and melatonin both appears to be ideal for using against lead induced oxidative damage of myocardium as both of them have been widely evaluated separately and have been found to possess very strong and all round protective action against lead induced oxidative stress mediated myocardial injury and in other human as well as animal situations.

**Acknowledgements:** Part of the work reported herein was supported from the funds available to Prof. DB under one of his Major Research Project of UGC, Govt. of India. Prof. DB also extends grateful thanks to UGC, Govt. of India, for the award of a Major Research Project under Centre with Potential for Excellence in a Particular Area (CPEPA) Scheme at University of Calcutta. DG gratefully



acknowledges the receipt of a Senior Research Fellowship (SRF) under INSPIRE program of Department of Science and Technology (DST), Government of India. Dr.AC is supported from funds available to her from a UGC Minor Research Project and DST WOS-A Scheme of Govt. of India. Technical helps which enriched the studies, from Parthabrata Roy (Technical Assistant, Chemical Engineering Department, C.U.), Tridib das, CRNN, University of Calcutta and Barindra Nath Mandal (Technical Officer B, Div of Mol Med, Bose Institute) and Dr. Roy's Diagnostics and Imaging Centre, Kolkata, is gratefully acknowledged.

## REFERENCES

- Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ, Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. *Lancet*, 367, 2009, 1747–1757.
- Kannel WB, Incidence and epidemiology of heart failure. *Heart Fail Rev*, 5, 2000, 167–173.
- Neubauer S, The failing heart: an engine out of fuel. *N Engl J Med*, 356, 2007, 1140–1151.
- Ungar I, Gilbert M, Siegel A, Blain J M, Bing R J, Studies on myocardial metabolism. IV. Myocardial metabolism in diabetes. *Am J Med*, 18, 1955, 385 – 396.
- COELHO, Vanessa Gregorin et al., Lipid profile and risk factors for cardiovascular diseases in medicine students. *Arq. Bras. Cardiol.* [online]. 2005, 85 (1) [cited 2014-08-27], 57-62. <http://dx.doi.org/10.1590/S0066-782X2005001400011>.
- Lakka TA, Bouchard C, Physical activity, obesity and cardiovascular diseases, *Handb Exp Pharmacol*, 2005, 170, 137-63.
- Liew CC, Dzau VJ, Molecular genetics and genomics of heart failure. *Nat Rev Gen*, 2004, 5:811– 825.
- O'Toole TE, Conklin DJ, Bhatnagar A, Environmental risk factors for heart disease, *Rev Environ Health*, 23(3), 2008,167-202.
- Pope III CA, Burnett RT, Thurston GD, Thun MJ, Calle EE, Krewski D, Godleski JJ, Cardiovascular Mortality and long-term exposure to particulate air pollution : epidemiological evidence of general pathophysiological pathways of disease, *Circulation*, 109, 2004, 71-77.
- Ghosh D, Firdaus S B, Mitra E, Dey M, Chattopadhyay A, Pattari S K, Dutta S, Jana K, Bandyopadhyay D, Aqueous leaf extract of *Murraya koenigii* protects against lead-induced cardio toxicity in male wistar rats, *International Journal of Phytopharmacology*, 4(2), 2013, 119-132.
- Ghosh D, Mitra E, Firdaus SB, Ghosh AK, Chattopadhyay A, Pattari SK, Bandyopadhyay D, Melatonin Protects Against Lead-Induced Cardio Toxicity: Involvement of Antioxidant Mechanis, *Int J Pharm Pharm Sci*, 5 (3),2013, 806-813.
- Mitra E, Ghosh D, Ghosh A K, Basu A, Chattopadhyay A, Pattari S K, Datta S, Bandyopadhyay D, Aqueous Tulsi Leaf (*Ocimum Sanctum*) Extract Possesses Antioxidant Properties And Protects Against Cadmium-Induced Oxidative Stress In Rat Heart, *Int J Pharm Pharm Sci*, 6 (1), 2014, 500-513.
- E Mitra, Ghosh AK, Ghosh D, Mukherjee D, Chattopadhyay A, Datta S, Pattari S K, Bandyopadhyay D, Protective effect of aqueous curry leaf ( *Murraya koenigii* ) extract against cadmium induced oxidative stress in rat heart, *Food and Chemical Toxicology*, 50 (5), 2012, 1340–1353.
- Hernberg S, Lead Poisoning in a Historical Perspective, *American Journal of Industrial Medicine*, 38, 2000, 244 – 254.
- Kehoe RA, Occupational lead poisoning. 2. Chemical signs of the absorption of lead. *J Occup Med*, 14, 1972, 390±399.
- Moore JE, Community aspects of childhood lead poisoning. *Am J Public Health*, 60, 1970, 1430-1438.
- Mayers MR, A study of the lead line, arteriosclerosis and hypertension in 381 lead workers, *J Ind Hyg*, 9, 1927, 239-250.
- Legge TM, Goadby KW, Lead poisoning and lead absorption. New York: Longman. 1912.
- Mishra S, Ghosh D, Dutta M, Chattopadhyay A, Bandyopadhyay D, Melatonin protects against lead-induced oxidative stress in stomach,duodenum and spleen of male wistar rats, *JPR:BioMedRx: An International Journal*, 2013, 1(11),997-1004.
- Paul S, Ghosh D, Ghosh A K, Dey M, Chattopadhyay A, Bandyopadhyay D, lead Induces Oxidative Stress In Rat Heart And Liver Tissue Homogenates: An In Vitro Study, *Journal of Cell And Tissue Research*, 13(3), 2013, 3829-3837.
- Nawrot TS, Thijs L, Den Hond EM, Roels HA, Staessen JA, An epidemiological re-appraisal of the association between blood pressure and blood lead: a meta-analysis, *J Hum Hypertens*, 16, 2002, 123-31.
- ND Vaziri, HC Gonick, Cardiovascular effects of lead exposure, *Indian J Med Res*, 128, 2008, 426-435.
- Nilsson U, Attewell R, Christoffersson JO, Schutz A, Ahlgren L, Skerfving S, et al., Kinetics of lead in bone and blood after end of occupational exposure. *Pharmacol Toxicol*, 68, 1991, 477-84.
- Ghosh D, Dey M, Ghosh A K, Chattopadhyay A, Bandyopadhyay D, Melatonin protects against lead acetate-induced changes in blood corpuscles and lipid profile of male Wistar rats. *Journal of Pharmacy Research* 2014, 8(3), 336-342.
- [www.clinicalkey.com/topics/gerontology/acute-myocardial-infarction.html](http://www.clinicalkey.com/topics/gerontology/acute-myocardial-infarction.html)
- Charlotte P, Anna B, Myocardial Injury: Contrasting Infarction and Contusion, *Crit Care Nurse*, 22 (1) , 2002 , 15-26.
- <http://medical-dictionary.thefreedictionary.com/myocardial+injury>
- KS Reddy, S Yusuf, Current Perspectives. Emerging Epidemic of Cardiovascular Disease in Developing Countries, *Circulation*, 97, 1998, 596-601
- Kodavanti UP, Moyer CF, Ledbetter AD, Schladweiler MC, Costa DL, Hauser R, Christiani DC, Nyska A, Inhaled environmental combustion particles cause myocardial



- injury in the Wistar Kyoto rat, *Toxicol Sci*, 71 (2), 2003, 237-45.
30. Alissa EM, Ferns G A, Heavy Metal Poisoning and Cardiovascular Disease, *Journal of Toxicology*, 2011, 1-21.
  31. Dutta M, Ghosh D, Ghosh A K, Rudra S, Bose G, Dey M, Bandyopadhyay A, Pattari S K, Mallick S, Chattopadhyay A, Bandyopadhyay D, High fat diet aggravates arsenic induced oxidative stress in rat heart and liver, *Food and Chemical Toxicology*, 66, 2014, 262–277.
  32. Payal B, Kaur H P, Rai Dv, New insight into the effects of lead modulation on antioxidant defense mechanism and trace element concentration in rat bone, *Interdisc Toxicol*, 2(1), 2009, 18–23.
  33. Casalone R, Granata P, Minelli E, Portentoso P, Giudici A, Righi R, Castelli P, Socrate A, Frigerio B, Cytogenetic analysis reveals clonal proliferation of smooth muscle cells in atherosclerotic plaques, *Hum Genet*, 87, 1991, 139–143.
  34. Mahmoudi M, J Mercer, M Bennett, DNA damage and repair in atherosclerosis, *Cardiovascular Research*, 71, 2006, 259 – 268.
  35. Tsutsui H, Ide T, Kinugawa S, Mitochondrial oxidative stress, DNA damage, and heart failure, *Antioxid Redox Signal*, 8 (9-10), 2006, 1737- 44.
  36. Sabri A, Hughie HH, Lucchesi PA, Regulation of hypertrophic and apoptotic signaling pathways by reactive oxygen species in cardiac myocytes, *Antioxid Redox Signal*, 2003, 5(6), 731-40.
  37. Lustberg M, Silbergeld E, Blood lead levels and mortality, *Arch Intern Med*, 162, 2002, 2443–2449.
  38. Menke A, Muntner P, Batuman V, Silbergeld EK, Guallar E, Blood lead below 0.48 micromol/L (10 microg/dL) and mortality among US adults, *Circulation*, 114, 2006, 1388–1394.
  39. Schober SE, Mirel LB, Graubard BI, Brody DJ, Flegal KM, Blood lead levels and death from all causes, cardiovascular disease, and cancer: results from the NHANES III Mortality Study, *Environ Health Perspect* 114, 2006, 1538–1541.
  40. Cheng Y, Schwartz J, Vokonas PS, Weiss ST, Aro A, Hu H, Electrocardiographic conduction disturbances in association with low-level lead exposure (the Normative Aging Study), *Am J Cardiol*, 82, 1998, 594–599.
  41. Schwartz J, Lead, blood pressure, and cardiovascular disease. in men and women, *Environ Health Perspect*, 91, 1991, 71–75.
  42. Szkup-Jablonska M, The effect of lead and cadmium on the lipid profile and psychosocial functioning of children with developmental disorders, *Ann Acad Med Stetin*, 57(2), 2011, 69-77.
  43. Sharma S V, Kumar P, Atam V, Verma A, Murthy R C, Lipid Profiles with Increase Blood Lead Level: Risk of Cardiovascular Disease in Battery Workers of Lucknow City, *J Indian Acad Forensic Med*, 2012, 34(4), 328-331.
  44. Chang HR, Chen SS, Chen TJ, Ho CK, Chiang HC, Yu HS, Lymphocyte  $\beta$ 2-adrenergic receptors and plasma catecholamine levels in lead-exposed workers, *Toxicol Appl Pharmacol*, 139, 1996, 1-5.
  45. Sharifi AM, Darabi R, Akbarloo N, Larijani B, Khoshbaten A, Investigation of circulatory and tissue ACE activity during development of lead-induced hypertension, *Toxicol Lett*, 153, 2004, 233-238.
  46. Gonick HC, Ding Y, Bondy SC, Ni Z, Vaziri ND, Lead-induced hypertension: interplay of nitric oxide and reactive oxygen species, *Hypertension*, 30, 1997, 1487-1492.
  47. Vaziri N, Ding Y, Effect of lead on nitric oxide synthase expression in coronary endothelial cells: role of superoxide, *Hypertension*, 37, 2001, 223-6.
  48. Cardenas A, Roels H, Bernard AM, Barbon R, Buchet JP, Lauwerys RR, J Roselló, G Hotter, A Mutti, I Franchini, Markers of early renal changes induced by industrial pollutants. II. Application to workers exposed to lead, *Br J Ind Med*, 50, 1993, 28-36.
  49. Hotter G, Fels LM, Closa D, Roselló J, Stolte H, Gelpí E, Altered levels of urinary prostanoids in lead-exposed workers, *Toxicol Lett*, 77, 1995, 309-312.
  50. Molero L, Carrasco C, Marques M, Vaziri ND, Mateos-Caceres PJ, Casado S, C Macaya<sup>1</sup>, A Barrientos<sup>2</sup> and A J López-Farré, Involvement of endothelium and endothelin-1 in lead-induced smooth muscle cell dysfunction in rats, *Kidney Int*, 69, 2006, 685-690.
  51. Dorman RV, Freeman EJ, Lead-dependent effects on arachidonic acid accumulation and the proliferation of vascular smooth muscle, *J Biochem Mol Toxicol*, 16, 2002, 245-53.
  52. Giridhar J, Isom GE, Interaction of lead acetate with atrial natriuretic factor in rats, *Life Sci*, 46, 1990, 569-576.
  53. Watts SW, Chai S, Webb RC, Lead acetate-induced contraction in rabbit mesenteric artery: interaction with calcium and protein kinase C, *Toxicology*, 99, 99, 55-65.
  54. Goldstein GW, Evidence that lead acts as a calcium substitute in second messenger metabolism, Presented at: Ninth International Neurotoxicology Conference, 1991, Little Rock, AR. *Neurotoxicology*, 14, 1993, 97-101.
  55. Simons TJB, Lead transport and binding by human erythrocytes *in vitro*, *Pflügers Arch*, 432, 1993, 307-13.
  56. Verna S, Fedak PWM, Weisel RD, Butany J, Rao V, Maitland A, Li R, Dhillon B, Yau TM, Fundamentals of Reperfusion injury for the Clinical Cardiologist, *Circulation*, 105, 2002, 2332-2336.
  57. Ghosh D, Firdaus S B, Ghosh A K, Paul S, Bandyopadhyay D, Protection against lead-induced oxidative stress in liver and kidneys of male Wistar rats using melatonin and aqueous extracts of the leaves of *Murraya koenigii* – A novel combinatorial therapeutic approach, *Journal of Pharmacy Research*, 8(3), 2014, 385-399.

Source of Support: Nil, Conflict of Interest: None.

